2017 Innovation Grants - Professor Brendan Jenkins
New therapeutic tools
This project aims to show the preclinical efficacy of a novel series of immune-based therapies across a range of human pancreatic tumours which have been genetically screened to predict treatment responsiveness. This project also addresses the need to identify new genes that can be the target of novel therapeutic approaches.

Professor Brendan Jenkins, Hudson Institute of Medical Research
Research Reports
Click to download progress reporting on the outcomes of this research.